BIOMAT Database Logo BIOMAT Database Logo

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. 1995

A Lipton, and L M Demers, and H A Harvey, and K B Kambic, and H Grossberg, and C Brady, and H Adlercruetz, and P F Trunet, and R J Santen
Department of Medicine, M. S. Hershey Medical Center, Pennsylvania State University, Hershey 17033, USA.

BACKGROUND Letrozole (CGS 20267), a triazole derivative, is a new, once-daily, oral nonsteroidal inhibitor of aromatase activity. METHODS In this Phase I trial, 23 heavily pretreated postmenopausal patients with metastatic breast cancer received letrozole at doses ranging from 0.1 to 5.0 mg once daily. RESULTS No hematologic, biochemical, or significant clinical toxicity was encountered. Serial steroid measurements were determined in 19 of these patients. Letrozole at all doses tested produced a marked suppression of plasma estrone, estradiol, estrone sulfate, and urine estrone and estradiol. This was observed within 24 hours of the initial dose of letrozole and resulted in a greater than 90% suppression of plasma and urinary estrogen levels within 2 weeks. Letrozole appears to be highly selective in its action and does not compromise glucocorticoid or mineralocorticoid production or thyroid function. Of the 21 evaluable patients, there were 2 with partial responses and 7 with stable disease. CONCLUSIONS Letrozole is a well tolerated, potent, and specific inhibitor of estrogen biosynthesis in postmenopausal patients with metastatic breast cancer.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009376 Neoplasms, Hormone-Dependent Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment. Hormone-Dependent Neoplasms,Hormone Dependent Neoplasms,Hormone-Dependent Neoplasm,Neoplasm, Hormone-Dependent,Neoplasms, Hormone Dependent
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004965 Estrogen Antagonists Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. Estradiol Antagonists,Antagonists, Estradiol,Antagonists, Estrogen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077289 Letrozole A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women. 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile),CGS 20267,CGS-20267,Femara,Fémara,CGS20267

Related Publications

A Lipton, and L M Demers, and H A Harvey, and K B Kambic, and H Grossberg, and C Brady, and H Adlercruetz, and P F Trunet, and R J Santen
[CGS 20267 (Letrozole), a new aromatase inhibitor: early phase II study for postmenopausal women with advanced breast cancer].
April 2002, Gan to kagaku ryoho. Cancer & chemotherapy,
A Lipton, and L M Demers, and H A Harvey, and K B Kambic, and H Grossberg, and C Brady, and H Adlercruetz, and P F Trunet, and R J Santen
Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients.
January 1996, Acta oncologica (Stockholm, Sweden),
A Lipton, and L M Demers, and H A Harvey, and K B Kambic, and H Grossberg, and C Brady, and H Adlercruetz, and P F Trunet, and R J Santen
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
January 1993, Cancer research,
A Lipton, and L M Demers, and H A Harvey, and K B Kambic, and H Grossberg, and C Brady, and H Adlercruetz, and P F Trunet, and R J Santen
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women.
August 1993, The Journal of clinical endocrinology and metabolism,
A Lipton, and L M Demers, and H A Harvey, and K B Kambic, and H Grossberg, and C Brady, and H Adlercruetz, and P F Trunet, and R J Santen
Intratumoral aromatase model: the effects of letrozole (CGS 20267).
January 1998, Breast cancer research and treatment,
A Lipton, and L M Demers, and H A Harvey, and K B Kambic, and H Grossberg, and C Brady, and H Adlercruetz, and P F Trunet, and R J Santen
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
January 1994, Breast cancer research and treatment,
A Lipton, and L M Demers, and H A Harvey, and K B Kambic, and H Grossberg, and C Brady, and H Adlercruetz, and P F Trunet, and R J Santen
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
December 1995, Clinical cancer research : an official journal of the American Association for Cancer Research,
A Lipton, and L M Demers, and H A Harvey, and K B Kambic, and H Grossberg, and C Brady, and H Adlercruetz, and P F Trunet, and R J Santen
CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study.
November 1990, Annals of oncology : official journal of the European Society for Medical Oncology,
A Lipton, and L M Demers, and H A Harvey, and K B Kambic, and H Grossberg, and C Brady, and H Adlercruetz, and P F Trunet, and R J Santen
Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.
December 1990, The Journal of steroid biochemistry and molecular biology,
A Lipton, and L M Demers, and H A Harvey, and K B Kambic, and H Grossberg, and C Brady, and H Adlercruetz, and P F Trunet, and R J Santen
Paradoxical effect of an aromatase inhibitor, CGS 20267, on aromatase activity in guinea pig brain.
July 1996, The Journal of steroid biochemistry and molecular biology,
Copied contents to your clipboard!